Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease

Thyroid

Volumn 17, Issue 12, 2007, Pages 1229-1234

  Kim, Kyung Won ^a   Park, Young Joo ^a,b   Kim, Tae Yong ^c   Park, Do Joon ^a   Park, Kyong Soo ^a   Cho, Bo Youn ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN; THYROTROPIN BINDING INHIBITORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXON; FEMALE; GENDER; GENETIC MARKER; GENOTYPE; GOITER; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RELAPSE; REMISSION; THYROTOXICOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ALLELES; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, DIFFERENTIATION; ANTITHYROID AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GRAVES DISEASE; HUMANS; MALE; METHIMAZOLE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROPYLTHIOURACIL; RECURRENCE; TREATMENT OUTCOME;

EID: 37849010932     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0011     Document Type: Article

References (34)

1. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M 1991 Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1:129-135.
2. Tominaga T, Yokoyama N, Nagataki S, Cho BY, Koh CS, Chen JL, Shi Y 1997 International differences in approaches to 131I therapy for Graves' disease: case selection and restrictions recommended to patients in Japan, Korea, and China. Thyroid 7:217-220.
3. Cho BY, Koh CS 1992 Current trends in the diagnosis and treatment of Graves' disease in Korea. J Korean Soc Endocrinol 7:216-227.
4. Berglund J, Christensen SB, Dymling JF, Hallengren B 1991 The incidence of recurrence and hypothyroidism following treatment with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis in Malmo during the period 1970-1974. J Intern Med 229:435-442.
5. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS 2005 A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 153:489-498.
6. McGregor AM, Smith BR, Hall R, Petersen MM, Miller M, Dewar PJ 1980 Prediction of relapse in hyperthyroid Graves' disease. Lancet 1:1101-1103.
7. Cooper DS 2005 Antithyroid drugs. N Engl J Med 352:905-917.
8. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR 1989 Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 120:689-701.
9. Weber KJ, Solorzano CC, Lee JK, Gaffud MJ, Prinz RA 2006 Thyroidectomy remains an effective treatment option for Graves' disease. Am J Surg 191:400-405.
10. Wille T, Muller B, Noth D, Burgi U, Diem P 2006 Long-term follow up after antithyroid drug treatment in Graves' disease. Schweiz Rundsch Med Prax 95:1121-1127.
11. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A 1997 Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7:369-375.
12. Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H 1998 Is there a methimazole dose effect on remission rate in Graves' disease? Results from a longterm prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf ) 49:451-457.
13. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P 1998 The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 8:119-124.
14. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, SaafM,Hamberger B 1996Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine - a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 81:2986-2993.
15. Ban Y, Tozaki T, Taniyama M, Tomita M, Ban Y 2006 Association of a C/T single-nucleotide polymorphism in the 5′ untranslated region of the CD40 gene with Graves' disease in Japanese. Thyroid 16:443-446.
16. Dittmar M, Kahaly GJ 2005 Immunoregulatory and susceptibility genes in thyroid and polyglandular autoimmunity. Thyroid 15:239-250.
17. Park YJ, Chung HK, Park DJ, Kim WB, Kim SW, Koh JJ, Cho BY 2000 Polymorphism in the promoter and exon 1 of the cytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans. Thyroid 10:453-459.
18. Tomer Y, Concepcion E, Greenberg DA 2002 A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. Thyroid 12:1129-1135.
19. Kim TY, Park YJ, Hwang JK, Song JY, Park KS, Cho BY, Park DJ 2003 A C/T polymorphism in the 5′-untranslated region of the CD40 gene is associated with Graves' disease in Koreans. Thyroid 13:919-925.
20. Sahin M, Erdogan MF, Erdogan G 2005 Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves' disease patients and association with probability of remission after antithyroid therapy. Eur J Intern Med 16: 352-355.
21. Wang PW, Liu RT, Juo SH, Wang ST, Hu YH, Hsieh CJ, Chen MH, Chen IY, Wu CL 2004 Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal. J Clin Endocrinol Metab 89:169-173.
22. Kim WB, Chung HK, Park YJ, Park DJ, Tahara K, Kohn LD, Cho BY 2000 The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease. Thyroid 10:579-586.
23. Kim TY, Park YJ, Park DJ, Chung HK, Kim WB, Kohn LD, Cho BY 2003 Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs. J Clin Endocrinol Metab 88:117-124.
24. Ban Y, Tozaki T, Taniyama M, Tomita M, Ban Y 2005 Association of a CTLA-4 3′ untranslated region (CT60) single nucleotide polymorphism with autoimmune thyroid disease in the Japanese population. Autoimmunity 38:151-153.
25. Park MH, Park YJ, Song EY, Park H, Kim TY, Park DJ, Park KS, Cho BY 2005 Association of HLA-DR and -DQ genes with Graves' disease in Koreans. Hum Immunol 66:740-746.
26. Davies TE 2005 Graves' disease. In: Braverman LE, Utiger RD (eds) The Thyroid: A Fundamental and Clinical Text. 9 edition. Lippincott Williams & Wilkins, Philadelphia, PA, pp 457-473.
27. Einarsdottir E, Soderstrom I, Lofgren-Burstrom A, Haraldsson S, Nilsson-Ardnor S, Penha-Goncalves C, Lind L, Holmgren G, Holmberg M, Asplund K, Holmberg D 2003 The CTLA4 region as a general autoimmunity factor: an extended pedigree provides evidence for synergy with the HLA locus in the etiology of type 1 diabetes mellitus, Hashimoto's thyroiditis and Graves' disease. Eur J Hum Genet 11:81-84.
28. Kinjo Y, Takasu N, Komiya I, Tomoyose T, Takara M, Kouki T, Shimajiri Y, Yabiku K, Yoshimura H 2002 Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene. J Clin Endocrinol Metab 87:2593-2596.
29. Petrone A, Giorgi G, Galgani A, Alemanno I, Corsello SM, Signore A, Di MU, Nistico L, Cascino I, Buzzetti R 2005 CT60 single nucleotide polymorphisms of the cytotoxic Tlymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. Thyroid 15: 232-238.
30. Weng YC, Wu MJ, Lin WS 2005 CT60 single nucleotide polymorphism of the CTLA-4 gene is associated with susceptibility to Graves' disease in the Taiwanese population. Ann Clin Lab Sci 35:259-264.
31. Cho HJ, Chung JH, Kim IS, Kim HJ, Cho SH, Ki CS, Kim JW 2006 Lack of a genetic association between the CTLA-4 gene and Graves' disease in Koreans. Thyroid 16:237-241.
32. Allannic H, Fauchet R, Lorcy Y, Gueguen M, Le Guerrier AM, Genetet B 1983 A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype. J Clin Endocrinol Metab 57:719-722.
33. Young ET, Steel NR, Taylor JJ, Stephenson AM, Stratton A, Holcombe M, Kendall-Taylor P 1988 Prediction of remission after antithyroid drug treatment in Graves' disease. Q J Med 66:175-189.
34. Takahashi M, Yasunami M, Kubota S, Tamai H, Kimura A 2006 HLA-DPB1*0202 is associated with a predictor of good prognosis of Graves' disease in the Japanese. Hum Immunol 67:47-52.